{"id":"carboplatin-auc-5-iva","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (thrombocytopenia, neutropenia, anemia)"},{"rate":"40-80","effect":"Nausea and vomiting"},{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"5-10","effect":"Peripheral neuropathy"},{"rate":"1-5","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, disrupting DNA synthesis and repair mechanisms. This leads to cell cycle arrest and programmed cell death in rapidly dividing cancer cells. The AUC (Area Under the Curve) dosing of 5 represents a personalized dosing approach based on renal function and other patient factors to optimize efficacy while managing toxicity.","oneSentence":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cell replication and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:07:52.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors (Phase 2 investigational)"}]},"trialDetails":[{"nctId":"NCT07418931","phase":"PHASE2","title":"A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-05","conditions":"Advanced Squamous Non-Small Cell Lung Cancer","enrollment":108},{"nctId":"NCT07028918","phase":"EARLY_PHASE1","title":"A Prospective Single-Arm Study（NCLDR）","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-08-30","conditions":"Oral Squamous Cell Carcinoma (OSCC)","enrollment":35},{"nctId":"NCT01566240","phase":"PHASE3","title":"Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2012-11-08","conditions":"Cervical Cancer","enrollment":500},{"nctId":"NCT06575322","phase":"","title":"Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-09-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":302},{"nctId":"NCT06576180","phase":"","title":"Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-08-23","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":306},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT06419673","phase":"PHASE2","title":"Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Cervical Cancer","enrollment":240},{"nctId":"NCT05837052","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-05-15","conditions":"Unresectable Lung Non-Small Cell Carcinoma","enrollment":49},{"nctId":"NCT05489848","phase":"PHASE2, PHASE3","title":"Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2022-08-20","conditions":"Endometrial Cancer","enrollment":294},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT04772001","phase":"NA","title":"Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2021-03-12","conditions":"Uterine Cervical Neoplasms, Chemoradiotherapy, Angiogenesis","enrollment":53},{"nctId":"NCT01732640","phase":"PHASE1, PHASE2","title":"A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-12","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":9},{"nctId":"NCT00502203","phase":"PHASE2","title":"Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-08","conditions":"Mixed Tumor, Mullerian","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Carboplatin AUC 5 IVa","genericName":"Carboplatin AUC 5 IVa","companyName":"Gruppo Oncologico Italiano di Ricerca Clinica","companyId":"gruppo-oncologico-italiano-di-ricerca-clinica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cell replication and inducing apoptosis in cancer cells. Used for Various solid tumors (Phase 2 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}